Back to Search
Start Over
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial
- Source :
- European Heart Journal, 35, 2516-23, Lincoff, A M, Roe, M, Aylward, P, Galla, J, Rynkiewicz, A, Guetta, V, Zelizko, M, Kleiman, N, White, H, McErlean, E, Erlinge, D, Laine, M, Dos Santos Ferreira, J M, Goodman, S, Mehta, S, Atar, D, Suryapranata, H, Jensen, S E, Forster, T, Fernandez-Ortiz, A, Schoors, D, Radke, P, Belli, G, Brennan, D, Bell, G, Krucoff, M & PROTECTION AMI Investigators 2014, ' Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction : results of the PROTECTION AMI Randomized Controlled Trial ', European Heart Journal, vol. 35, no. 37, pp. 2516-2523 . https://doi.org/10.1093/eurheartj/ehu177, European Heart Journal, 35, 37, pp. 2516-23
- Publication Year :
- 2014
- Publisher :
- Oxford University Press (OUP), 2014.
-
Abstract
- Aims Delcasertib is a selective inhibitor of delta-protein kinase C (delta-PKC), which reduced infarct size during ischaemia/reperfusion in animal models and diminished myocardial necrosis and improved reperfusion in a pilot study during primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI). Methods and results A multicentre, double-blind trial was performed in patients presenting within 6 h and undergoing primary PCI for anterior (the primary analysis cohort, n = 1010 patients) or inferior (an exploratory cohort, capped at 166 patients) STEMI. Patients with anterior STEMI were randomized to placebo or one of three doses of delcasertib (50, 150, or 450 mg/h) by intravenous infusion initiated before PCI and continued for ∼2.5 h. There were no differences between treatment groups in the primary efficacy endpoint of infarct size measured by creatine kinase MB fraction area under the curve (AUC) (median 5156, 5043, 4419, and 5253 ng h/mL in the placebo, delcasertib 50, 150, and 450 mg/mL groups, respectively) in the anterior STEMI cohort. No treatment-related differences were seen in secondary endpoints of infarct size, electrocardiographic ST-segment recovery AUC or time to stable ST recovery, or left ventricular ejection fraction at 3 months. No differences in rates of adjudicated clinical endpoints (death, heart failure, or serious ventricular arrhythmias) were observed. Conclusions Selective inhibition of delta-PKC with intravenous infusion of delcasertib during PCI for acute STEMI in a population of patients treated according to contemporary standard of care did not reduce biomarkers of myocardial injury. Clinical trial registration ClinicalTrials.gov Identifier: [NCT00785954][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00785954&atom=%2Fehj%2Fearly%2F2014%2F05%2F05%2Feurheartj.ehu177.atom
- Subjects :
- Male
medicine.medical_specialty
medicine.medical_treatment
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]
Population
Myocardial Infarction
Infarction
Pilot Projects
Drug Administration Schedule
Percutaneous Coronary Intervention
Reperfusion therapy
Double-Blind Method
Internal medicine
medicine
Creatine Kinase, MB Form
Humans
ST segment
cardiovascular diseases
Myocardial infarction
Infusions, Intravenous
education
Protein Kinase Inhibitors
Aged
education.field_of_study
Ejection fraction
business.industry
Troponin I
Percutaneous coronary intervention
Middle Aged
medicine.disease
Treatment Outcome
Chemotherapy, Adjuvant
Area Under Curve
Conventional PCI
Cardiology
Female
Peptides
Cardiology and Cardiovascular Medicine
business
Biomarkers
Subjects
Details
- ISSN :
- 15229645, 0195668X, and 00785954
- Volume :
- 35
- Database :
- OpenAIRE
- Journal :
- European Heart Journal
- Accession number :
- edsair.doi.dedup.....b488880ac21774290f5d0ceccbcd8622
- Full Text :
- https://doi.org/10.1093/eurheartj/ehu177